Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study - PubMed (original) (raw)
Randomized Controlled Trial
Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study
Matthew J Worley et al. Alcohol Clin Exp Res. 2015 Jan.
Abstract
Background: Oral naltrexone is an efficacious medication for treatment of alcohol dependence, but small effect sizes and variability in outcomes suggest the presence of person-level moderators of naltrexone response. Identification of contextual or psychosocial moderators may assist in guiding clinical recommendations. Given the established importance of social networks in drinking outcomes, as well as the potential effects of naltrexone in reducing cue reactivity which may be especially important among those with more heavy drinkers and more alcohol cues in their networks, we examined pretreatment social network variables as potential moderators of naltrexone treatment effects in the COMBINE study.
Methods: The sample included all COMBINE study participants in medication conditions with full data on the Important People Inventory (IPI) and covariates at intake (N = 1,197). The intake IPI assessed whether participants had any frequent drinkers in their network and the average frequency of contact with these drinkers. The effects of treatment condition, pretreatment network variables, and their interactions on percent heavy drinking days were tested in hierarchical linear models, controlling for demographics and baseline clinical covariates.
Results: In treatment conditions involving medical management and combined behavioral intervention (CBI), the effects of active naltrexone on heavy drinking were significantly greater for individuals with frequent drinkers in their network (z = -2.66, p < 0.01) and greater frequency of contact with those drinkers (z = -3.19, p < 0.01). These network variables did not moderate the effects of active naltrexone without CBI.
Conclusions: When delivered in conjunction with behavioral interventions, naltrexone can be more potent for alcohol-dependent adults who have greater contact with frequent drinkers prior to treatment, which may indicate patterns of environmental exposure to alcohol. Contextual, social risk factors are a potential avenue to guide personalized treatment of alcohol dependence.
Keywords: Alcohol Dependence; Moderators; Naltrexone; Pharmacotherapy; Social Network.
Copyright © 2015 by the Research Society on Alcoholism.
Figures
Fig. 1
Interaction between weekly drinker network and treatment condition effects on percent heavy drinking days during treatment.
Fig. 2
Interaction between drinker contact frequency and treatment condition effects on percent heavy drinking days during treatment.
Similar articles
- Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group. Anton RF, et al. JAMA. 2006 May 3;295(17):2003-17. doi: 10.1001/jama.295.17.2003. JAMA. 2006. PMID: 16670409 Clinical Trial. - Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Greenfield SF, et al. Alcohol Clin Exp Res. 2010 Oct;34(10):1803-12. doi: 10.1111/j.1530-0277.2010.01267.x. Epub 2010 Jul 20. Alcohol Clin Exp Res. 2010. PMID: 20645934 Free PMC article. - Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C, Kahler CW, Swift RM, O'Malley SS. Capone C, et al. J Stud Alcohol Drugs. 2011 Jan;72(1):135-40. doi: 10.15288/jsad.2011.72.135. J Stud Alcohol Drugs. 2011. PMID: 21138720 Clinical Trial. - The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. Pettinati HM, et al. J Clin Psychopharmacol. 2006 Dec;26(6):610-25. doi: 10.1097/01.jcp.0000245566.52401.20. J Clin Psychopharmacol. 2006. PMID: 17110818 Review. - Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
Volpicelli JR, Volpicelli LA, O'Brien CP. Volpicelli JR, et al. Alcohol Alcohol. 1995 Nov;30(6):789-98. Alcohol Alcohol. 1995. PMID: 8679021 Review.
Cited by
- Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR, Mann K, Witkiewitz K. Roos CR, et al. Addict Biol. 2017 Nov;22(6):1528-1539. doi: 10.1111/adb.12427. Epub 2016 Aug 2. Addict Biol. 2017. PMID: 27480445 Free PMC article. Clinical Trial. - Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Witkiewitz K, Roos CR, Mann K, Kranzler HR. Witkiewitz K, et al. Alcohol Clin Exp Res. 2019 Nov;43(11):2395-2405. doi: 10.1111/acer.14183. Epub 2019 Sep 11. Alcohol Clin Exp Res. 2019. PMID: 31436886 Free PMC article. Clinical Trial. - Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Witkiewitz K, Pearson MR, Hallgren KA, Maisto SA, Roos CR, Kirouac M, Wilson AD, Montes KS, Heather N. Witkiewitz K, et al. Addiction. 2017 Dec;112(12):2112-2121. doi: 10.1111/add.13870. Epub 2017 Jun 26. Addiction. 2017. PMID: 28511286 Free PMC article. - An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.
Gueorguieva R, Wu R, Tsai WM, O'Connor PG, Fucito L, Zhang H, O'Malley SS. Gueorguieva R, et al. Eur Neuropsychopharmacol. 2015 Oct;25(10):1586-99. doi: 10.1016/j.euroneuro.2015.06.006. Epub 2015 Jun 20. Eur Neuropsychopharmacol. 2015. PMID: 26141511 Free PMC article. Clinical Trial. - Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
Mann K, Roos CR, Hoffmann S, Nakovics H, Leménager T, Heinz A, Witkiewitz K. Mann K, et al. Neuropsychopharmacology. 2018 Mar;43(4):891-899. doi: 10.1038/npp.2017.282. Epub 2017 Nov 20. Neuropsychopharmacology. 2018. PMID: 29154368 Free PMC article. Clinical Trial.
References
- Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996;53:225–231. - PubMed
- Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758–1764. - PubMed
- Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, Locastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, Group CSR. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017. - PubMed
- Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135–144. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical